The RAPID-COVID consortium is made up of 5 partners from 4 European countries (UK, France, Spain, Slovenia) and constitutes a pan-European eco-system with the necessary infrastructure, knowledge, expertise, services and industry value chain to succeed in delivering on the project’s objectives to realised the expected impacts of the IMI call topic.
Assistance Publique Hospitaux de Paris
Assistance Publique Hospitaux de Paris is a public health establishment and university hospital center - CHU - in the Ile-de-France region. It is the largest employer in Ile-de-France with 100,000 employees including doctors, researchers, paramedics, administrative staff. The AP-HP brings together 39 hospitals, located in Paris, in the inner suburbs and in the provinces. For this project, APHP, with its expertise in microbiology and infectious diseases testing, will be validating the high-throughput platform against current state-of-the-art system.
Agencia Sanitaria Costa del Sol
Agencia Sanitaria Costa del Sol (HCS) is a health organization that belongs to the Andalusian Ministry of Health. It constitutes 3 Hospitals with 2,000 professionals and covers a population of around 500,000 citizens allocated in the Costa del Sol region. Its mission is to provide public quality health care to the citizens, seeking efficiency and optimum use of resources with links to 12 Primary care centres in the area. HCS has vast expertise in clinical trials, epidemiological studies and health care improvement interventions. HCS is a clinical validation partner for both the Point-of-Care and High-throughput testing platforms for this project.
BIOSISTEMIKA LLC specializes in life science laboratory automation and workflow management, actively working in the biotechnology area. It is composed of an interdisciplinary team of software engineers, computer programmers and life science experts. BioSistemika will develop an user-friendly software for automated platforms for the Covid-19 laboratory assay, developed by consortium partner GeneFirst.
Genefirst is a molecular diagnostics company focused on infectious diseases, cancer diagnostics and personalised medicine. It offers robust, easy-to-use and sensitive molecular diagnostics solutions to researchers, clinicians and drug companies to enable accurate diagnosis and delivery of safe and effective medicines.
PrimaDiag develops automates for Genomics and molecular biology. Its clients are mainly hospitals, diagnostic laboratories and research centers. One of the company's flagship products is the ACSIA platform, which prepares samples for next-generation sequencers (NGS). PrimaDiag will be responsible for automating the workflow for efficient high-throughput testing.